EU/3/21/2464: Orphan designation for the treatment of follicular lymphoma

Tisagenlecleucel contains the patient’s own T cells (a type of white blood cell) that have been modified genetically in the laboratory so that they make a protein called chimeric antigen receptor (CAR). CAR can attach to another protein on the surface of cancer cells called CD19.

When the medicine is given to the patient, the modified T cells (called CAR-T cells) attach to and kill the cancer cells, thereby helping to clear the cancer from the body.

At the time of submission of the application for orphan designation:

• The effects of the medicine had been evaluated in experimental models.

• Clinical trials with the medicine in patients with follicular lymphoma were ongoing.

Tisagenlecleucel is authorised in the EU under the name Kymriah for treating 2 types of blood cancer: B-cell acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL).

More information on how potential new medicines are tested during their development is available on Authorisation of medicines

Medicines intended for rare diseases can be granted an orphan designation during their development.

The orphan designation allows the developer to benefit from:

• scientific and regulatory support to advance their medicine to the stage where they can request marketing authorisation;

• market exclusivity once the medicine is on the market.

To qualify for orphan designation, a medicine must meet a number of criteria:

• it must be intended for the treatment, prevention or diagnosis of a disease that is life-threatening or chronically debilitating;

• the prevalence of the condition in the EU must not be more than 5 in 10,000 or it must be unlikely that marketing of the medicine would generate sufficient returns to justify the investment needed for its development;

• there are no satisfactory alternative methods for the diagnosis, prevention or treatment of the condition or the medicine is of significant benefit to those affected by the condition.

EMA's Committee for Orphan Medicinal Products (COMP) is responsible for issuing opinions on applications for orphan designations.

The Agency sends the COMP opinion to the European Commission, which is responsible for granting the orphan designation. The full list of orphan designations is available in the Community register of orphan medicinal products for human use.

For more information, see:

• Orphan designation: Overview
• Rare diseases, orphan medicines: Getting the facts straight